Contact Dermatitis: Therapeutics When Avoidance Fails

Welsh, Esperanza; Goldenberg, Alina; Welsh, Oliverio; Jacob, Sharon E.

doi:10.4172/2155-6121.1000185

Cited by 4 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first reaction is the sensitization phase, followed by the elicitation phase, which is characterized by skin inflammation mediated by proinflammatory cytokines [ 10 ]. ACD is commonly treated with glucocorticoids, which also increase the risk of undesirable effects such as hypertension, diabetes, and cataracts [ 11 ]. Therefore, topical skin preparations that are safer and have a lower risk of side effects are expected to serve as therapeutic agents for ACD.…”

Section: Introductionmentioning

confidence: 99%

The Antioxidant PAPLAL Protects against Allergic Contact Dermatitis in Experimental Models

Shibuya,

Watanabe,

Shimizu

2024

Antioxidants

View full text Add to dashboard Cite

PAPLAL, a mixture of platinum (nPt) and palladium (nPd) nanoparticles, is widely used as a topical agent because of its strong antioxidant activity. Allergic contact dermatitis (ACD) is one of the most common occupational skin diseases worldwide. However, the role of oxidative stress in ACD remains unclear. In the present study, we investigated the protective effects of topical PAPLAL treatment on 2,4-dinitrofluorobenzene (DNFB)-induced ACD. DNFB treatment increased 8-isoprostane content; upregulated Xdh, Nox2, and Nox4, pro-oxidant genes; and downregulated Sod1, an antioxidant gene, indicating oxidative damage in the ear skin. PAPLAL therapy significantly reduced ear thickness associated with the downregulation of inflammatory cytokine-related genes. PAPLAL also significantly increased the expression of the stress-response-related genes Ahr and Nrf2, as well as their target genes, but failed to alter the expression of redox-related genes. Furthermore, Sod1 loss worsened ACD pathologies in the ear. These results strongly suggest that PAPLAL protects against ACD through its antioxidant activity and activation of the AHR and NRF2 axes. The antioxidant PAPLAL can be used as a novel topical therapy for ACD that targets oxidative stress.

show abstract

Section: Introductionmentioning

confidence: 99%

The Antioxidant PAPLAL Protects against Allergic Contact Dermatitis in Experimental Models

Shibuya,

Watanabe,

Shimizu

2024

Antioxidants

View full text Add to dashboard Cite

show abstract

“…Also, medical management includes topical corticosteroid, oral retinoids and immunosuppressive drugs, and phototherapy. 9 These medications have significant side effects along with their effectiveness and there are limited numbers of published placebo-controlled studies of other therapeutic interventions. 8,10,11 Therefore, researches are being conducted to discover effective drugs with fewer side effects.…”

Section: Introductionmentioning

confidence: 99%

“…The treatment cornerstone for CD is avoidance from exposure. Also, medical management includes topical corticosteroid, oral retinoids and immunosuppressive drugs, and phototherapy 9 . These medications have significant side effects along with their effectiveness and there are limited numbers of published placebo‐controlled studies of other therapeutic interventions 8,10,11 .…”

Section: Introductionmentioning

confidence: 99%

Efficacy of oral supplementation of whey protein in patients with contact dermatitis: A pilot randomized double‐blind placebo‐controlled clinical trial

Alyasin

Nabavizadeh

Esmaeilzadeh

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Whey protein is a popular dietary product that has numerous health benefits such as immune modulation. In this study, we assessed efficacy of whey protein in management of patients with contact dermatitis (CD) through a double blind, randomized controlled clinical trial in Emam Reza clinic, Shiraz, Iran. Twenty-five patients in each group were randomly assigned to receive whey protein or placebo powder, 30 g in 200 mL warm water at fasting time for 4 weeks. Outcome measures were Dermatology Life Quality Index (DLQI) questionnaire and the Eczema Area and Severity Index (EASI) score. Furthermore, subjective total improvement (assessed by visual analogue scale) was set as the other primary outcome measure. A significant decrease was observed in the scores of EASI, DLQI, and subjective total improvement in the drug group after the intervention compared with the baseline. However, no changes were seen in the placebo group. Moreover, there was a significant reduction in the scores of EASI (P = .002) and subjective total improvement scores (P = .039) over the study period in the drug group compared with the placebo group. According to the results of this study, it seems that oral supplementation of whey protein could improve the symptoms of CD compared with placebo.

show abstract

“…The prevalence rate of ACD is higher in young children under 10 years than it is adults [ 3 , 6 ]. Systemic corticosteroid or steroids combined with methotrexate, and azathioprine have been used for ACD [ 7 ]. However, long-term use of these drugs can cause unwanted side effects such as diabetes, hypertension, myelosuppression, infections, and ulcer [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

“…Systemic corticosteroid or steroids combined with methotrexate, and azathioprine have been used for ACD [ 7 ]. However, long-term use of these drugs can cause unwanted side effects such as diabetes, hypertension, myelosuppression, infections, and ulcer [ 7 ]. Therefore, there is a need to develop novel agents, preferably from natural products, to treat ACD [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Pediococcus pentosaceus-Fermented Cordyceps militaris Inhibits Inflammatory Reactions and Alleviates Contact Dermatitis

Kwon

Song

Lee

et al. 2018

IJMS

View full text Add to dashboard Cite

Cordyceps militaris is a medicinal mushroom used to treat immune-related diseases in East Asia. We investigated the anti-inflammatory effect of the extract of C. militaris grown on germinated Rhynchosia nulubilis (GRC) fermented with Pediococcus pentosaceus ON89A isolated from onion (GRC-ON89A) in vivo as well as in vitro. The anti-inflammatory effect of GRC-ON89A was investigated in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages. The total polyphenol content (TPC) and total flavonoid content (TFC) in the GRC-ON89A ethanol extract were significantly increased compared to that in GRC. GRC-ON89A hexane fraction (GRC-ON89A-Hex) inhibited the release of nitric oxide (NO) compared to that of the LPS-treated control without cytotoxicity in LPS-stimulated RAW 264.7 macrophages. GRC-ON89A-Hex decreased the inducible NO synthase (iNOS), cyclooxygenase 2 (COX2), and tumor necrosis factor (TNF)-α mRNA expression in LPS-stimulated RAW 264.7 macrophages. In addition, pre-treatment with GRC-ON89A-Hex significantly inhibited LPS-stimulated phosphorylation of mitogen-activated protein kinases (MAPKs) and nuclear factor (NF)-κB. To induce allergic contact dermatitis (ACD), 1-fluoro-2, 4-dinitrofluorobenzene (DNFB) was applied to the surface of the right ears of C57BL/6N mice. GRC-ON89A reduced the ear swelling and thickness in DNFB-induced ACD mice. This study demonstrates the potential usefulness of GRC-ON89A as an anti-inflammatory dietary supplement or drug.

show abstract

Contact Dermatitis: Therapeutics When Avoidance Fails

Cited by 4 publications

References 20 publications

The Antioxidant PAPLAL Protects against Allergic Contact Dermatitis in Experimental Models

The Antioxidant PAPLAL Protects against Allergic Contact Dermatitis in Experimental Models

Efficacy of oral supplementation of whey protein in patients with contact dermatitis: A pilot randomized double‐blind placebo‐controlled clinical trial

Pediococcus pentosaceus-Fermented Cordyceps militaris Inhibits Inflammatory Reactions and Alleviates Contact Dermatitis

Contact Info

Product

Resources

About